scholarly journals A Partially Humanized Monoclonal Antibody to Human IFN-γ Inhibits Cytokine Effects both In Vitro and In Vivo

2002 ◽  
Vol 55 (3) ◽  
pp. 284-292 ◽  
Author(s):  
S. Fiorentini ◽  
G. De Panfilis ◽  
G. Pasolini ◽  
C. Bonfanti ◽  
A. Caruso
Keyword(s):  
Monoclonal Antibody ◽  
Humanized Monoclonal Antibody ◽  
Ifn Γ

scholarly journals Organic Nanocarriers for Bevacizumab Delivery: An Overview of Development, Characterization and Applications

Molecules ◽  
2021 ◽  
Vol 26 (14) ◽  
pp. 4127
Author(s):  
Aline de Cristo Soares Alves ◽  
Franciele Aline Bruinsmann ◽  
Silvia Stanisçuaski Guterres ◽  
Adriana Raffin Pohlmann
Keyword(s):  
Monoclonal Antibody ◽  
Physicochemical Characterization ◽  
Vascular Endothelial ◽  
Organic Nanoparticles ◽  
Humanized Monoclonal Antibody ◽  
Angiogenesis Process ◽  
Endothelial Growth Factor ◽  
Drug Pharmacokinetics

Bevacizumab (BCZ) is a recombinant humanized monoclonal antibody against the vascular endothelial growth factor, which is involved in the angiogenesis process. Pathologic angiogenesis is observed in several diseases including ophthalmic disorders and cancer. The multiple administrations of BCZ can cause adverse effects. In this way, the development of controlled release systems for BCZ delivery can promote the modification of drug pharmacokinetics and, consequently, decrease the dose, toxicity, and cost due to improved efficacy. This review highlights BCZ formulated in organic nanoparticles providing an overview of the physicochemical characterization and in vitro and in vivo biological evaluations. Moreover, the main advantages and limitations of the different approaches are discussed. Despite difficulties in working with antibodies, those nanocarriers provided advantages in BCZ protection against degradation guaranteeing bioactivity maintenance.

scholarly journals In vitro and In vivo Characterization of 64Cu-Labeled AbegrinTM, a Humanized Monoclonal Antibody against Integrin αvβ3

2006 ◽  
Vol 66 (19) ◽  
pp. 9673-9681 ◽  
Author(s):  
Weibo Cai ◽  
Yun Wu ◽  
Kai Chen ◽  
Qizhen Cao ◽  
David A. Tice ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Integrin Αvβ3 ◽  
Humanized Monoclonal Antibody ◽  
In Vivo Characterization

scholarly journals Humanized Monoclonal Antibody That Passively Protects Mice against Systemic and Intranasal Ricin Toxin Challenge

2016 ◽  
Vol 23 (9) ◽  
pp. 795-799 ◽  
Author(s):  
Greta Van Slyke ◽  
Erin K. Sully ◽  
Natasha Bohorova ◽  
Ognian Bohorov ◽  
Do Kim ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Lethal Dose ◽  
Murine Monoclonal Antibody ◽  
Serum Concentrations ◽  
Immunodominant Epitope ◽  
Ricin Toxin ◽  
Humanized Monoclonal Antibody

ABSTRACTPB10 is a murine monoclonal antibody against an immunodominant epitope on ricin toxin's enzymatic subunit. Here, we characterize a fully humanized version of PB10 IgG1 (hPB10) and demonstrate that it has potentin vitroandin vivotoxin-neutralizing activities. We also report the minimum serum concentrations of hPB10 required to protect mice against 10 times the 50% lethal dose of ricin when delivered by injection and inhalation.

scholarly journals Overexpression of Interleukin-15 Increases Susceptibility to Lipopolysaccharide-Induced Liver Injury in Mice Primed with Mycobacterium bovis Bacillus Calmette-Guérin

2004 ◽  
Vol 72 (7) ◽  
pp. 3855-3862 ◽  
Author(s):  
Toshiki Yajima ◽  
Hitoshi Nishimura ◽  
Kimika Saito ◽  
Hiroyuki Kuwano ◽  
Yasunobu Yoshikai
Keyword(s):  
Monoclonal Antibody ◽  
T Cells ◽  
Liver Injury ◽  
Mycobacterium Bovis ◽  
Bystander Activation ◽  
Highly Sensitive ◽  
Interleukin 15 ◽  
Ifn Γ

ABSTRACT Mice primed with Mycobacterium bovis bacillus Calmette-Guérin (BCG) are highly sensitive to lipopolysaccharide (LPS)-induced liver injury and lethality. We found that interleukin-15 (IL-15) transgenic (Tg) mice primed with BCG were more susceptible to LPS-induced liver injury than non-Tg mice. The numbers of CD44+ CD8+ T cells expressing intracellular gamma interferon (IFN-γ) significantly increased in the livers of BCG-primed IL-15 Tg mice after LPS injection, and the depletion of CD8+ T cells from BCG-primed IL-15 Tg mice completely abolished the susceptibility to LPS-induced lethality. Liver T cells from BCG-primed IL-15 Tg mice produced IFN-γ in vitro in response to LPS, which was inhibited by the addition of anti-IL-12 monoclonal antibody (MAb). In vivo treatment with anti-IL-12 MAb inhibited the appearance of CD44+ CD8+ T cells expressing intracellular IFN-γ after LPS injection. These results suggest that the overexpression of IL-15 increases susceptibility to LPS-induced liver injury in BCG-primed mice via bystander activation of CD8+ T cells.

scholarly journals Development of a Humanized Monoclonal Antibody (MEDI‐493) with Potent In Vitro and In Vivo Activity against Respiratory Syncytial Virus

1997 ◽  
Vol 176 (5) ◽  
pp. 1215-1224 ◽  
Author(s):  
Syd Johnson ◽  
Cynthia Oliver ◽  
Gregory A. Prince ◽  
Val G. Hemming ◽  
David S. Pfarr ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Respiratory Syncytial Virus ◽  
Humanized Monoclonal Antibody ◽  
Syncytial Virus

scholarly journals A Humanized Monoclonal Antibody Targeting Extracellular Nicotinamide Phosphoribosyltransferase Prevents Aggressive Prostate Cancer Progression

2021 ◽  
Vol 14 (12) ◽  
pp. 1322
Author(s):  
Belinda L. Sun ◽  
Lin Tang ◽  
Xiaoguang Sun ◽  
Alexander N. Garcia ◽  
Sara M. Camp ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Monoclonal Antibody ◽  
Cancer Progression ◽  
Unmet Need ◽  
Scid Mice ◽  
Therapeutic Effects ◽  
Nicotinamide Phosphoribosyltransferase ◽  
Humanized Monoclonal Antibody

Prostate cancer (PCa) is the major cause of cancer-related death in males; however, effective treatments to prevent aggressive progression remain an unmet need. We have previously demonstrated that secreted extracellular nicotinamide phosphoribosyltransferase (eNAMPT) is a multifunctional innate immunity regulator that promotes PCa invasion. In the current study, we further investigate the therapeutic effects of an eNAMPT-neutralizing humanized monoclonal antibody (ALT-100 mAb) in preclinical PCa orthotopic xenograft models. We utilized human aggressive PCa cells (DU145 or PC3) for prostate implantation in SCID mice receiving weekly intraperitoneal injections of either ALT-100 mAb or IgG/PBS (control) for 12 weeks. Prostatic tumors and solid organs were examined for tumor growth, invasion, and metastasis and for biochemical and immunohistochemistry evidence of NFκB activation. ALT-100 mAb treatment significantly improved overall survival of SCID mice implanted with human PCa orthotopic prostate xenografts while inducing tumor necrosis, decreasing PCa proliferation and reducing local invasion and distal metastases. The ALT-100 mAb inhibits NFκB phosphorylation and signaling in PCa cells both in vitro and in vivo. This study demonstrates that eNAMPT neutralization effectively prevents human PCa aggressive progression in preclinical models, indicating its high potential to directly address the unmet need for an effective targeted therapy for patients with aggressive PCa.

Sign in / Sign up

Export Citation Format

Share Document